Recently, the European Medicines Agency (EMA) officially released the revised Good Manufacturing Practice (GMP) guidelines for pharmaceutical lyophilization equipment, adding core requirements such as full-cycle control of equipment data traceability and verification of sterile isolation systems. With forward-looking compliance layout, LYOMAC has completed compliance upgrades for its entire range of medical lyophilizers (including industrial and pilot-scale models) and automatic loading/unloading systems, successfully passing the pre-audit by EU authoritative institutions, providing compliance guarantees for global customers to enter the European market.
According to the latest report from Transparency Market Research (TMR), the global market for pharmaceutical lyophilization equipment and services will expand at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2034, with the market size expected to exceed 13.48 billion USD by 2034. Intelligent and energy-efficient equipment has become a core growth driver. In response, LYOMAC is accelerating the R&D of AI-driven lyophilization process control systems. Its new-generation industrial lyophilizer has achieved intelligent optimization of the lyophilization cycle, reducing energy consumption by more than 15% compared with traditional equipment.
The US Food and Drug Administration (FDA) recently released the revised version of the "Guidance for Quality Control of Lyophilization Processes for Biological Products", further refining the lyophilization process verification standards for vaccines, monoclonal antibodies and other products, requiring enterprises to establish a full-process process parameter monitoring system. In response to this change, LYOMAC has quickly launched customized FDA compliance solutions, covering services such as upgrading of lyophilizer PLC data traceability systems and lyophilization process verification consulting, helping North American customers pass regulatory audits efficiently.
A major news came from the international biopharmaceutical field: the world's first injectable recombinant type Ⅲ humanized collagen gel adopting "honeycomb" collagen tissue network technology was officially launched in European and American markets. During the industrial production stage of this product, LYOMAC industrial lyophilizers and mobile AGV loading/unloading systems were adopted. With precise shelf temperature control (uniformity ±1℃) and sterile transfer capability, the stability of the product's active ingredients was guaranteed, helping it successfully pass the market access audits in Europe and the United States.
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) announced the addition of 3 new member states, expanding the coverage of its certification system to more than 50 countries and regions around the world. LYOMAC medical lyophilizers, relying on production processes and quality control systems that meet PIC/S GMP standards, have successfully obtained recognition from regulatory authorities in multiple countries such as Malaysia's NPRA and Australia's TGA, becoming a key recommended lyophilization equipment brand in Southeast Asian and Oceanian markets.
Recently, a well-known European pharmaceutical company announced the official commissioning of its first dual-chamber lyophilized preparation production line, which focuses on the production of long-acting biological products such as growth hormones. The fully automatic fixed vial row-by-row system (RBR) customized by LYOMAC for the line has successfully achieved seamless linkage with the dual-chamber lyophilizer. Through row-by-row precise transfer and sterile isolation design, it effectively reduces the contamination risk during the reconstitution process of preparations, gaining high recognition from the customer.
The World Health Organization (WHO) recently updated the "Global Guidelines for Procurement of Vaccine Production Equipment", clarifying the core technical parameter requirements for lyophilization equipment used in vaccine R&D and small-batch production. LYOMAC laboratory lyophilizers, with stable cold trap temperature control (≤-55℃), high-precision vacuum systems and flexible operation modes, have been successfully included in the WHO recommended equipment list, and will provide equipment support for vaccine R&D projects in low-income countries around the world.
In response to global "dual carbon" goals, Germany's Federal Ministry for the Environment issued a promotion policy for energy-saving equipment in the pharmaceutical industry, providing procurement subsidies for lyophilization equipment that meets energy efficiency class A standards. LYOMAC's inverter energy-saving medical lyophilizers developed for the European market have successfully met Germany's energy efficiency class A standards through core component optimization and intelligent inverter control technology. Currently, they have obtained bulk procurement orders from pharmaceutical companies in multiple European countries such as Germany and France.
The enterovirus 71 inactivated vaccine independently developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, has officially launched in the Southeast Asian market after passing PIC/S GMP certification. During the commercial production stage of this vaccine, LYOMAC provided full-process technical support from pilot scale to mass production, including lyophilization process optimization and equipment parameter calibration. Its supporting temperature, pressure and vacuum calibration equipment ensured the parameter stability during the vaccine lyophilization process.
LYOMAC recently announced a strategic cooperation with Nicomac, a well-known Italian pharmaceutical equipment enterprise. The two parties will integrate technical advantages to jointly develop intelligent lyophilization production lines adapted to the European market. This cooperation will focus on breaking through the linkage control technology between lyophilization equipment and solid preparation production lines. The first jointly developed product is expected to be launched in the first quarter of 2026, further enhancing LYOMAC's competitiveness in the European high-end medical equipment market.
